These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer. Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138 [TBL] [Abstract][Full Text] [Related]
3. CAR-T cell therapy in melanoma: A future success story? Simon B; Uslu U Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790 [TBL] [Abstract][Full Text] [Related]
4. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115 [TBL] [Abstract][Full Text] [Related]
5. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Burns WR; Zhao Y; Frankel TL; Hinrichs CS; Zheng Z; Xu H; Feldman SA; Ferrone S; Rosenberg SA; Morgan RA Cancer Res; 2010 Apr; 70(8):3027-33. PubMed ID: 20395199 [TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]
7. Adoptive cell transfer (ACT) of autologous tumor-infiltrating lymphocytes (TILs) to treat malignant melanoma: the dawn of a chimeric antigen receptor T (CAR-T) cell therapy from autologous donor. Roncati L; Palmieri B Int J Dermatol; 2020 Jul; 59(7):763-769. PubMed ID: 32441324 [TBL] [Abstract][Full Text] [Related]
8. Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers. Gargett T; Truong NTH; Gardam B; Yu W; Ebert LM; Johnson A; Yeo ECF; Wittwer NL; Tapia Rico G; Logan J; Sivaloganathan P; Collis M; Ruszkiewicz A; Brown MP J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754916 [TBL] [Abstract][Full Text] [Related]
9. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism. Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320 [TBL] [Abstract][Full Text] [Related]
10. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557 [TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives. Qu J; Mei Q; Chen L; Zhou J Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047 [TBL] [Abstract][Full Text] [Related]
12. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype. Gargett T; Truong N; Ebert LM; Yu W; Brown MP Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603 [TBL] [Abstract][Full Text] [Related]
14. Opportunities and obstacles for the melanoma immunotherapy using T cell and chimeric antigen receptor T (CAR-T) applications: a literature review. Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori H; Mansoori Y; Salahi A; Nikfar G; Tavassoli A; Behmard E; Moravej A; Ghasemian A Mol Biol Rep; 2022 Nov; 49(11):10627-10633. PubMed ID: 35715610 [TBL] [Abstract][Full Text] [Related]
15. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells. Morgan MA; Büning H; Sauer M; Schambach A Front Immunol; 2020; 11():1965. PubMed ID: 32903482 [TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T-cell therapy for melanoma. Razavi A; Keshavarz-Fathi M; Pawelek J; Rezaei N Expert Rev Clin Immunol; 2021 Mar; 17(3):209-223. PubMed ID: 33481629 [TBL] [Abstract][Full Text] [Related]
17. [Immunotherapy for cancer: from medical breakthrough to application in daily practice]. Dekker NRP; Stigt JA; Visser O; Netters FJS; Koornstra RHT; de Groot JWB Ned Tijdschr Geneeskd; 2019 May; 163():. PubMed ID: 31187969 [TBL] [Abstract][Full Text] [Related]
18. Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs. Forsberg EMV; Riise R; Saellström S; Karlsson J; Alsén S; Bucher V; Hemminki AE; Olofsson Bagge R; Ny L; Nilsson LM; Rönnberg H; Nilsson JA Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765608 [TBL] [Abstract][Full Text] [Related]
19. Engineering T Cells to Express Tumoricidal MDA-7/IL24 Enhances Cancer Immunotherapy. Liu Z; Guo C; Das SK; Yu X; Pradhan AK; Li X; Ning Y; Chen S; Liu W; Windle JJ; Bear HD; Manjili MH; Fisher PB; Wang XY Cancer Res; 2021 May; 81(9):2429-2441. PubMed ID: 33727225 [TBL] [Abstract][Full Text] [Related]
20. Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies. Guo Z; Tu S; Yu S; Wu L; Pan W; Chang N; Zhou X; Song C; Li Y; He Y Cancer Sci; 2021 Apr; 112(4):1357-1368. PubMed ID: 33416209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]